ENDPOINTS

Lilly's heart drug study shows potential for once-a-year dosing

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing treatments in development from Novartis and Amgen, giving Lilly a way into an intense competition ...

Mar 31, 2025 - 16:35
 0
Lilly's heart drug study shows potential for once-a-year dosing
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing treatments in development from Novartis and Amgen, giving Lilly a way into an intense competition ...
Read More

Tags:

Previous Article

US Space Force wants a new 'orbital carrier' to be a satellite launch pad in space

Next Article

Hyme Energy Advances Molten Salt Battery Technology

Related Posts

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Feb 10, 2025  0

Cerebral CEO David Mou has stepped down

Cerebral CEO David Mou has stepped down

Mar 3, 2025  0

Updates on health agency nominees; New data from Pfizer, Beam; MASH startup weighs IPO; and more

Updates on health agency nominees; New data from Pfizer...

Mar 15, 2025  0